Malaria Vaccines: Progressing on a Bumpy Road

Article history: Received 21 October 2014 Accepted 21 October 2014 Available online 23 October 2014 most advanced malaria vaccine candidate, the RTS,S vaccine based on the P. falciparum circumsporozoite (CS) protein, has gone through extensive testing in Africa where a recent phase 3 trial showed a 27 and 46% protection against clinical malaria in African infant and children respectively but unfortunately its efficacy wanes down in a relatively short time (The RTS, S Clinical Trials Partnership, 2014). The goal of the RTS,S Clinical Trial Partnership is now to seek a license for the first-generation